127 related articles for article (PubMed ID: 38763123)
1. Effect of Antacids on the Survival of Patients With Metastatic Urothelial Carcinoma Treated With Pembrolizumab.
Sekito T; Bekku K; Katayama S; Watanabe T; Tsuboi I; Yoshinaga K; Maruyama Y; Yamanoi T; Kawada T; Tominaga Y; Sadahira T; Iwata T; Nishimura S; Kusumi N; Edamura K; Kobayashi T; Kurose K; Ichikawa T; Miyaji Y; Wada K; Kobayashi Y; Araki M
Clin Genitourin Cancer; 2024 Aug; 22(4):102097. PubMed ID: 38763123
[TBL] [Abstract][Full Text] [Related]
2. Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab.
Hashimoto M; Fukuokaya W; Yanagisawa T; Yamamoto S; Koike Y; Imai Y; Iwatani K; Onuma H; Ito K; Urabe F; Tsuzuki S; Kimura S; Oyama Y; Abe H; Miki J; Kimura T
Int J Clin Oncol; 2024 May; 29(5):612-619. PubMed ID: 38430304
[TBL] [Abstract][Full Text] [Related]
3. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.
Cortellini A; Di Maio M; Nigro O; Leonetti A; Cortinovis DL; Aerts JG; Guaitoli G; Barbieri F; Giusti R; Ferrara MG; Bria E; D'Argento E; Grossi F; Rijavec E; Guida A; Berardi R; Torniai M; Sforza V; Genova C; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Della Gravara L; Inno A; Michele T; Grassadonia A; Di Marino P; Mansueto G; Zoratto F; Filetti M; Santini D; Citarella F; Russano M; Cantini L; Tuzi A; Bordi P; Minuti G; Landi L; Ricciardi S; Migliorino MR; Passiglia F; Bironzo P; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Friedlaender A; Addeo A; Cannita K; Ficorella C; Porzio G; Pinato DJ
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827906
[TBL] [Abstract][Full Text] [Related]
4. Impact of the Use of Proton Pump Inhibitors on Pembrolizumab Effectiveness for Advanced Urothelial Carcinoma.
Tomisaki I; Harada M; Minato A; Nagata Y; Kimuro R; Higashijima K; Harada K; Fujimoto N
Anticancer Res; 2022 Mar; 42(3):1629-1634. PubMed ID: 35220261
[TBL] [Abstract][Full Text] [Related]
5. Association Between Serum Magnesium Levels and Outcomes of Atezolizumab in Patients With Metastatic Urothelial Carcinoma.
Fukuokaya W; Akazawa K; Kimura T
Anticancer Res; 2024 May; 44(5):2117-2123. PubMed ID: 38677745
[TBL] [Abstract][Full Text] [Related]
6. Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
Uemura K; Ito H; Jikuya R; Kondo T; Tatenuma T; Kawahara T; Ito Y; Komeya M; Muraoka K; Hasumi H; Uemura H; Makiyama K
Int J Urol; 2024 Jun; 31(6):678-684. PubMed ID: 38402449
[TBL] [Abstract][Full Text] [Related]
7. Effects of Proton Pump Inhibitors on Survival Outcomes in Patients with Metastatic or Unresectable Urothelial Carcinoma Treated with Pembrolizumab.
Kunimitsu Y; Morio K; Hirata S; Yamamoto K; Omura T; Hara T; Harada K; Fujisawa M; Yano I
Biol Pharm Bull; 2022; 45(5):590-595. PubMed ID: 35491164
[TBL] [Abstract][Full Text] [Related]
8. Durable Response to Enfortumab Vedotin Compared to Re-challenging Chemotherapy in Metastatic Urothelial Carcinoma After Checkpoint Inhibitors.
Uchimoto T; Tsuchida S; Komura K; Fukuokaya W; Adachi T; Hirasawa Y; Hashimoto T; Yoshizawa A; Saruta M; Hashimoto M; Higashio T; Matsuda T; Nishimura K; Tsujino T; Nakamura K; Fukushima T; Nishio K; Yamamoto S; Iwatani K; Urabe F; Mori K; Yanagisawa T; Tsuduki S; Takahara K; Inamoto T; Miki J; Fujita K; Kimura T; Ohno Y; Shiroki R; Uemura H; Azuma H
Target Oncol; 2024 May; 19(3):401-410. PubMed ID: 38546942
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab.
Katayama S; Iwata T; Kawada T; Okamoto Y; Sano Y; Kawago Y; Miyake S; Moriwake T; Kuinose A; Horikawa Y; Tsuboi K; Tsuboi I; Sakaeda K; Nakatsuka H; Takamoto A; Hirata T; Shirasaki Y; Yamasaki T; Morinaka H; Nagasaki N; Hara T; Ochi A; Okumura M; Watanabe T; Sekito T; Kawano K; Horii S; Yamanoi T; Nagao K; Yoshinaga K; Maruyama Y; Tominaga Y; Sadahira T; Nishimura S; Edamura K; Kobayashi T; Kusumi N; Kurose K; Yamamoto Y; Sugimoto M; Nakada T; Sasaki K; Takenaka T; Ebara S; Miyaji Y; Wada K; Kobayashi Y; Araki M
Urol Oncol; 2024 Mar; 42(3):70.e11-70.e18. PubMed ID: 38129282
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial.
Nishiyama H; Yamamoto Y; Sassa N; Nishimura K; Fujimoto K; Fukasawa S; Yokoyama M; Enokida H; Takahashi K; Tanaka Y; Imai K; Shimamoto T; Perini R; Frenkl T; Bajorin D; Bellmunt J
Int J Clin Oncol; 2020 Jan; 25(1):165-174. PubMed ID: 31729625
[TBL] [Abstract][Full Text] [Related]
11. Predictive Impact of Prognostic Nutritional Index on Pembrolizumab for Metastatic Urothelial Carcinoma Resistant to Platinum-based Chemotherapy.
Ishiyama Y; Kondo T; Nemoto Y; Kobari Y; Ishihara H; Tachibana H; Yoshida K; Hashimoto Y; Takagi T; Iizuka J; Tanabe K
Anticancer Res; 2021 Mar; 41(3):1607-1614. PubMed ID: 33788756
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy.
Tully KH; Jütte H; Wirtz RM; Jarczyk J; Santiago-Walker A; Zengerling F; Breyer J; Sikic D; Kriegmair MC; von Hardenberg J; Wullich B; Taubert H; Weyerer V; Stoehr R; Bolenz C; Burger M; Porubsky S; Hartmann A; Roghmann F; Erben P; Eckstein M
Urology; 2021 Nov; 157():93-101. PubMed ID: 34153367
[TBL] [Abstract][Full Text] [Related]
13. Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab.
Kobayashi T; Ito K; Kojima T; Kato M; Kanda S; Hatakeyama S; Matsui Y; Matsushita Y; Naito S; Shiga M; Miyake M; Muro Y; Nakanishi S; Kato Y; Shibuya T; Hayashi T; Yasumoto H; Yoshida T; Uemura M; Taoka R; Kamiyama M; Ogawa O; Kitamura H; Nishiyama H;
Cancer Sci; 2021 Feb; 112(2):760-773. PubMed ID: 33283385
[TBL] [Abstract][Full Text] [Related]
14. Effect of Antacid Use on Immune Checkpoint Inhibitors in Advanced Solid Cancer Patients: A Systematic Review and Meta-analysis.
Deng R; Zhang H; Li Y; Shi Y
J Immunother; 2023 Feb-Mar 01; 46(2):43-55. PubMed ID: 36301729
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of Pembrolizumab for Patients with Advanced, Unresectable, or Metastatic Urothelial Cancer Ineligible for Cisplatin-based Therapy.
Patterson K; Prabhu V; Xu R; Li H; Meng Y; Zarabi N; Zhong Y; Batteson R; Pellissier J; Keefe S; Grivas P; de Wit R
Eur Urol Oncol; 2019 Sep; 2(5):565-571. PubMed ID: 31412011
[TBL] [Abstract][Full Text] [Related]
16. Associations of Acid Suppressive Therapy With Cardiac Mortality in Heart Failure Patients.
Yoshihisa A; Takiguchi M; Kanno Y; Sato A; Yokokawa T; Miura S; Abe S; Misaka T; Sato T; Suzuki S; Oikawa M; Kobayashi A; Yamaki T; Kunii H; Nakazato K; Suzuki H; Saitoh SI; Takeishi Y
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28512114
[TBL] [Abstract][Full Text] [Related]
17. Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study.
Miller NJ; Khaki AR; Diamantopoulos LN; Bilen MA; Santos V; Agarwal N; Morales-Barrera R; Devitt M; Nelson A; Hoimes CJ; Shreck E; Assi H; Gartrell BA; Sankin A; Rodriguez-Vida A; Lythgoe M; Pinato DJ; Drakaki A; Joshi M; Isaacsson Velho P; Hahn N; Liu S; Alonso Buznego L; Duran I; Moses M; Jain J; Murgic J; Barata P; Tripathi A; Zakharia Y; Galsky MD; Sonpavde G; Yu EY; Lyman GH; Grivas P
J Urol; 2020 Jul; 204(1):63-70. PubMed ID: 31971495
[TBL] [Abstract][Full Text] [Related]
18. Expressions of PD-L1 and Nectin-4 in urothelial cancer patients treated with pembrolizumab.
Ueki H; Hinata N; Kitagawa K; Hara T; Terakawa T; Furukawa J; Harada K; Nakano Y; Komatsu M; Fujisawa M; Shirakawa T
Clin Transl Oncol; 2022 Mar; 24(3):568-577. PubMed ID: 34687441
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes.
Esagian SM; Khaki AR; Diamantopoulos LN; Carril-Ajuria L; Castellano D; De Kouchkovsky I; Park JJ; Alva A; Bilen MA; Stewart TF; McKay RR; Santos VS; Agarwal N; Jain J; Zakharia Y; Morales-Barrera R; Devitt ME; Nelson A; Hoimes CJ; Shreck E; Gartrell BA; Sankin A; Tripathi A; Zakopoulou R; Bamias A; Rodriguez-Vida A; Drakaki A; Liu S; Kumar V; Lythgoe MP; Pinato DJ; Murgic J; Fröbe A; Joshi M; Isaacsson Velho P; Hahn N; Alonso Buznego L; Duran I; Moses M; Barata P; Galsky MD; Sonpavde G; Yu EY; Msaouel P; Koshkin VS; Grivas P
BJU Int; 2021 Aug; 128(2):196-205. PubMed ID: 33556233
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study.
Parikh M; Pan CX; Beckett LA; Li Y; Robles DA; Aujla PK; Lara PN
Clin Genitourin Cancer; 2018 Dec; 16(6):421-428.e1. PubMed ID: 30166228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
